TABLE 4

Treatment modifications by deprivation quintile in the Salford Lung Study (SLS) of COPD and SLS asthma (total study populations and SLS asthma inhaled corticosteroid (ICS)/long-acting β2-agonist (LABA) therapy subset#)

Deprivation quintileSLS COPD (n=2791) SLS asthma (n=4218)ICS/LABA therapy subset (n=2642)
PatientsFF/VI (n=1396)UC (n=1395)PatientsFF/VI (n=2105)UC (n=2113)PatientsFF/VI (n=1319)UC (n=1323)
11453n=731
181 (25%)
n=722
78 (11%)
855n=412
82 (20%)
n=443
113 (26%)
551n=268
62 (23%)
n=283
80 (28%)
2601n=307
69 (22%)
n=294
37 (13%)
834n=434
94 (22%)
n=400
65 (16%)
526n=276
59 (21%)
n=250
40 (16%)
3391n=189
40 (21%)
n=202
19 (9%)
856n=401
89 (22%)
n=455
80 (18%)
551n=252
54 (21%)
n=299
50 (17%)
4209n=104
26 (25%)
n=105
16 (15%)
831n=425
94 (22%)
n=406
64 (16%)
511n=265
61 (23%)
n=246
44 (18%)
5137n=65
26 (40%)
n=72
10 (14%)
842n=433
103 (24%)
n=409
53 (13%)
503n=258
73 (28%)
n=245
37 (15%)

Data area presented as the n (%) patients with one or more treatment modification during the study. FF/VI: fluticasone furoate/vilanterol; UC: usual care. #: the SLS asthma ICS/LABA therapy subset comprised patients whose baseline maintenance therapy per randomisation stratification and pre-randomisation prescription was an ICS/LABA; : where 1 is the most deprived and 5 is the least deprived.